{"id":"NCT00982930","sponsor":"Novartis Pharmaceuticals","briefTitle":"Open Label Extension to Bridging Study CTBM100C2303","officialTitle":"A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08-12","primaryCompletion":"2011-10","completion":"2011-10-06","firstPosted":"2009-09-23","resultsPosted":"2021-06-02","lastUpdate":"2021-06-02"},"enrollment":55,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pseudomonas Aeruginosa","Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Tobramycin inhalation powder","otherNames":[]}],"arms":[{"label":"Tobramycin Inhalation Powder (TIP)","type":"EXPERIMENTAL"}],"summary":"This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas aeruginosa (P. aeruginosa) at enrollment into CTBM100C2303.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs)","timeFrame":"From first administration of study drug to study completion (up to approximately 25 weeks)","effectByArm":[{"arm":"Tobramycin Inhalation Powder","deltaMin":47.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":2,"countries":["Estonia","Russia"]},"refs":{"pmids":["26709158"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":55},"commonTop":["Respiratory tract infection","Cough","Hypoacusis","Dysphonia","Abdominal pain"]}}